Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells

Cell Cycle

Volumn 12, Issue 9, 2013, Pages 1433-1449

  Diep, Caroline H ^a   Charles, Nathan J ^a   Gilks, C Blake ^b   Kalloger, Steve E ^b   Argenta, Peter A ^c   Lange, Carol A ^a,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AS1842856; Breast cancer; Forkhead transcription factor; FOXO1; Ovarian cancer; P21; Progesterone receptor; Progestin; Senescence

Indexed keywords

BETA GALACTOSIDASE; GESTAGEN; PROGESTERONE RECEPTOR; PROTEIN P15; PROTEIN P16; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR FKHR;

ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CELL STRUCTURE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; OVARY CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SENESCENCE; UPREGULATION;

EID: 84877134423     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24550     Document Type: Article

References (95)

1. Cancer Facts & Figures. Atlanta: American Cancer Society 2012
2. Lange CA, Yee D. Progesterone and breast cancer. Womens Health (Lond Engl) 2008; 4:151-62; PMID:19072517; http://dx.doi.org/10.2217/17455057.4.2.151
3. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem 2002; 277:27793-800; PMID:12021276; http://dx.doi.org/10.1074/jbc.M202584200
4. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277:5209-18; PMID:11717311; http://dx.doi.org/10.1074/jbc.M110090200
5. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003; 100:9744-9; PMID:12897242; http://dx.doi.org/10.1073/ pnas.1732707100
6. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000; 289:1751-4; PMID:10976068; http://dx.doi.org/10.1126/science.289.5485.1751
7. Wei LL, Norris BM, Baker CJ. An N-terminally truncated third progesterone receptor protein, PR(C), forms heterodimers with PR(B) but interferes in PR(B)-DNA binding. J Steroid Biochem Mol Biol 1997; 62:287-97; PMID:9408082; http://dx.doi.org/10.1016/S0960-0760(97)00044-7
8. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003; 1:73; PMID:14577831; http://dx.doi.org/10.1186/1477-7827-1-73
9. Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 2007; 17:325-38; PMID:17362310; http://dx.doi.org/10.1111/j.1525-1438.2006.00749.x
10. Beral V, Doll R, Hermon C, Peto R, Reeves G; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371:303-14; PMID:18294997; http://dx.doi.org/10.1016/S0140-6736(08)60167-1
11. Hempling RE, Piver MS, Eltabbakh GH, Recio FO. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol 1998; 21:447-51; PMID:9781597; http://dx.doi.org/10.1097/00000421-199810000-00005
12. Münstedt K, Steen J, Knauf AG, Buch T, von Georgi R, Franke FE. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 2000; 89:1783-91; PMID:11042574; http://dx.doi.org/10.1002/1097- 0142(20001015)89:8<1783::AIDCNCR19>3.0.CO;2-D
13. Sinn BV, Darb-Esfahani S, Wirtz RM, Budczies J, Sehouli J, Chekerov R, et al. Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathology 2011; 59:918-27; PMID:22092403; http://dx.doi.org/10.1111/j.1365- 2559.2011.04028.x
14. Lindgren P, Bäckström T, Mählck CG, Ridderheim M, Cajander S. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol 2001; 19:31-8; PMID:11408919
15. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer 2000; 83:1488-94; PMID:11076658; http://dx.doi.org/10.1054/bjoc.2000.1463
16. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005; 96:671-7; PMID:15721410; http://dx.doi.org/10.1016/j.ygyno.2004.11.010
17. Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007; 18:1051-9; PMID:17914554
18. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer 2009; 19:620-7; PMID:19509560; http://dx.doi.org/10.1111/IGC.0b013e3181a44b62
19. Yang XY, Xi MR, Yang KX, Yu H. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecol Oncol 2009; 113:99-104; PMID:19178934; http://dx.doi.org/10.1016/j. ygyno.2008.12.018
20. Dressing GE, Lange CA. Integrated actions of progesterone receptor and cell cycle machinery regulate breast cancer cell proliferation. Steroids 2009; 74:573-6; PMID:19118566; http://dx.doi.org/10.1016/j.steroids.2008.12.001
21. Migliaccio A, Castoria G, Di Domenico M, Ballaré C, Beato M, Auricchio F. The progesterone receptor/estradiol receptor association and the progestintriggered S-phase entry. Ernst Schering Res Found Workshop 2005:39-54; PMID:15704467; http://dx.doi.org/10.1007/3-540-27147-3-3
22. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000; 19:5406-17; PMID:11032808; http://dx.doi.org/10.1093/emboj/19.20.5406
23. Skildum A, Faivre E, Lange CA. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 2005; 19:327-39; PMID:15486045; http://dx.doi.org/10.1210/me.2004-0306
24. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone- independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 2005; 19:574-87; PMID:15563544; http://dx.doi.org/10. 1210/me.2004-0287
25. McGowan EM, Russell AJ, Boonyaratanakornkit V, Saunders DN, Lehrbach GM, Sergio CM, et al. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res 2007; 67:8942-51; PMID:17875737; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-1255
26. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998; 5:271-6; PMID:9773403; http://dx.doi.org/10.1016/S1071-5576(98)00017-3
27. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002; 94:50-60; PMID:11773282; http://dx.doi.org/10.1093/jnci/94.1.50
28. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001; 61:6768-76; PMID:11559549
29. Syed V, Ho SM. Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 2003; 22:6883-90; PMID:14534535; http://dx.doi.org/10.1038/sj. onc.1206828
30. Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Daraï E. Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 2006; 15:743-8; PMID:16525653
31. Zhou H, Luo MP, Schönthal AH, Pike MC, Stallcup MR, Blumenthal M, et al. Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther 2002; 1:300-6; PMID:12432283
32. Horiuchi S, Kato K, Suga S, Takahashi A, Ueoka Y, Arima T, et al. Expression of progesterone receptor B is associated with G0/G1 arrest of the cell cycle and growth inhibition in NIH3T3 cells. Exp Cell Res 2005; 305:233-43; PMID:15817149; http://dx.doi.org/10.1016/j.yexcr.2005.01.003
33. Takahashi A, Kato K, Kuboyama A, Inoue T, Tanaka Y, Kuhara A, et al. Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol Oncol 2009; 113:270-6; PMID:19211137; http://dx.doi.org/10.1016/j.ygyno.2008.12.032
34. Lenhard M, Tereza L, Heublein S, Ditsch N, Himsl I, Mayr D, et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 2012; 12:553; PMID:23176303; http://dx.doi.org/10.1186/1471-2407-12-553
35. Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, et al. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol 2001; 25:667-72; PMID:11342781; http://dx.doi.org/10.1097/00000478-200105000-00016
36. Itani OA, Liu KZ, Cornish KL, Campbell JR, Thomas CP. Glucocorticoids stimulate human sgk1 gene expression by activation of a GRE in its 5'-flanking region. Am J Physiol Endocrinol Metab 2002; 283:E971-9; PMID:12376324
37. Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D, Lange CA. The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol 2010; 24:2126-38; PMID:20861224; http://dx.doi.org/10.1210/me.2010- 0170
38. Lau DH, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991; 51:5181-7; PMID:1717140
39. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS ONE 2011; 6:e21121; PMID:21754983; http://dx.doi.org/10.1371/ journal.pone.0021121
40. Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, et al. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 1994; 54:3868-77; PMID:8033109
41. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol 2003; 17:628-42; PMID:12554776; http://dx.doi.org/10.1210/me.2002- 0378
42. Ivarsson K, Sundfeldt K, Brännström M, Janson PO. Production of steroids by human ovarian surface epithelial cells in culture: possible role of progesterone as growth inhibitor. Gynecol Oncol 2001; 82:116-21; PMID:11426972; http://dx.doi.org/10.1006/gyno.2001.6219
43. Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997; 79:1944-50; PMID:9149021; http://dx.doi.org/10.1002/ (SICI)1097-0142(19970515)79:10<1944::AIDCNCR15>3.0.CO;2-V
44. Yu S, Lee M, Shin S, Park J. Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem 2001; 82:445-51; PMID:11500921; http://dx.doi.org/10.1002/jcb.1171
45. Keith Bechtel M, Bonavida B. Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol 2001; 82:127-38; PMID:11426974; http://dx.doi.org/10.1006/gyno.2001.6221
46. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007; 27:466-80; PMID:17074804; http://dx.doi.org/10.1128/MCB. 01539-06
47. Daniel AR, Faivre EJ, Lange CA. Phosphorylationdependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol 2007; 21:2890-906; PMID:17717077; http://dx.doi.org/10.1210/me.2007- 0248
48. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120:513-22; PMID:15734683; http://dx.doi.org/10.1016/j.cell.2005.02.003
49. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363-7; PMID:7568133; http://dx.doi.org/ 10.1073/pnas.92.20.9363
50. Bayreuther K, Rodemann HP, Hommel R, Dittmann K, Albiez M, Francz PI. Human skin fibroblasts in vitro differentiate along a terminal cell lineage. Proc Natl Acad Sci USA 1988; 85:5112-6; PMID:3393534; http://dx.doi.org/10.1073/ pnas.85.14.5112
51. Darzynkiewicz Z, Sharpless T, Staiano-Coico L, Melamed MR. Subcompartments of the G1 phase of cell cycle detected by flow cytometry. Proc Natl Acad Sci USA 1980; 77:6696-9; PMID:6161370; http://dx.doi.org/10.1073/pnas. 77.11.6696
52. Darzynkiewicz Z, Juan G, Srour EF. Differential staining of DNA and RNA. Current protocols in cytometry/editorial board, J Paul Robinson, managing editor [et al] 2004; Chapter 7:Unit 7 3
53. Shapiro HM. Flow cytometric estimation of DNA and RNA content in intact cells stained with Hoechst 33342 and pyronin Y. Cytometry 1981; 2:143-50; PMID:6170496; http://dx.doi.org/10.1002/cyto.990020302
54. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-40; PMID:17667954; http://dx.doi.org/10.1038/nrm2233
55. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14; PMID:19440234; http://dx.doi.org/10. 1038/nrc2657
56. Borgdorff V, Lleonart ME, Bishop CL, Fessart D, Bergin AH, Overhoff MG, et al. Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene 2010; 29:2262-71; PMID:20101223; http://dx.doi.org/10. 1038/onc.2009.497
57. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277:831-4; PMID:9242615; http://dx.doi.org/10.1126/science.277.5327.831
58. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7:3355-61; PMID:18948731; http://dx.doi.org/10.4161/cc.7.21.6919
59. Takano M, Lu Z, Goto T, Fusi L, Higham J, Francis J, et al. Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol 2007; 21:2334-49; PMID:17609436; http://dx.doi.org/10.1210/me.2007-0058
60. Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, Singh DK, et al. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 2008; 149:1942-50; PMID:18096667; http://dx.doi.org/10. 1210/en.2007-0756
61. Goto T, Takano M, Hirata J, Tsuda H. The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. Br J Cancer 2008; 98:1068-75; PMID:18319717; http://dx.doi.org/10.1038/sj.bjc. 6604279
62. Tang Q, Chen Y, Meyer C, Geistlinger T, Lupien M, Wang Q, et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res 2011; 71:6940-7; PMID:21940749; http://dx.doi.org/10.1158/0008-5472.CAN-11-2091
63. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, et al. Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78:961-70; PMID:20736318; http://dx.doi.org/10.1124/mol.110.065714
64. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 122:33-43; PMID:16009131; http://dx.doi.org/10.1016/j.cell.2005.05.008
65. Dressing GE, Hagan CR, Knutson TP, Daniel AR, Lange CA. Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer 2009; 16:351-61; PMID:19357196; http://dx.doi.org/10.1677/ ERC-08-0281
66. Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal 2009; 7:e009; PMID:20087430
67. Charles NJ, Thomas P, Lange CA. Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesteroneinduced signaling events. Horm Cancer 2010; 1:167-76; PMID:21761364; http://dx.doi.org/10.1007/s12672-010-0023-9
68. Peluso JJ. Non-genomic actions of progesterone in the normal and neoplastic mammalian ovary. Semin Reprod Med 2007; 25:198-207; PMID:17447209; http://dx.doi.org/10.1055/s-2007-973432
69. Hanna R, Pang Y, Thomas P, Zhu Y. Cell-surface expression, progestin binding, and rapid nongenomic signaling of zebrafish membrane progestin receptors alpha and beta in transfected cells. J Endocrinol 2006; 190:247-60; PMID:16899559; http://dx.doi.org/10.1677/joe.1.06694
70. Thomas P, Pang Y, Dong J, Groenen P, Kelder J, de Vlieg J, et al. Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology 2007; 148:705-18; PMID:17082257; http://dx.doi.org/10.1210/en.2006-0974
71. Daniel AR, Knutson TP, Lange CA. Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol 2009; 308:47-52; PMID:19549591; http://dx.doi.org/10.1016/j.mce.2009.01.004
72. Clement PB. Histology of the ovary. Am J Surg Pathol 1987; 11:277-303; PMID:3565674; http://dx.doi.org/10.1097/00000478-198704000-00006
73. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19:833-42; PMID:15695368; http://dx.doi.org/10.1210/me.2004- 0486
74. Lange CA. Integration of progesterone receptor action with rapid signaling events in breast cancer models. J Steroid Biochem Mol Biol 2008; 108:203-12; PMID:17964138; http://dx.doi.org/10.1016/j.jsbmb.2007.09.019
75. Weigel NL, Moore NL. Kinases and protein phosphorylation as regulators of steroid hormone action. Nucl Recept Signal 2007; 5:e005; PMID:17525795
76. Alberts B, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. Garland Science, 2002
77. Hill KK, Roemer SC, Churchill ME, Edwards DP. Structural and functional analysis of domains of the progesterone receptor. Mol Cell Endocrinol 2012; 348:418-29; PMID:21803119; http://dx.doi.org/10.1016/j.mce.2011.07.017
78. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010; 11:9-22; PMID:20027184; http://dx.doi.org/10.1038/nrm2822
79. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 1998; 273:31317-26; PMID:9813040; http://dx.doi.org/10.1074/jbc.273.47.31317
80. Christian M, Pohnke Y, Kempf R, Gellersen B, Brosens JJ. Functional association of PR and CCAAT/enhancer-binding protein beta isoforms: promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. Mol Endocrinol 2002; 16:141-54; PMID:11773445; http://dx.doi.org/10.1210/me.16.1.141
81. Kim JJ, Buzzio OL, Li S, Lu Z. Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biol Reprod 2005; 73:833-9; PMID:15987820; http://dx.doi.org/10.1095/biolreprod.105.043182
82. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7:847-59; PMID:17943136; http://dx.doi.org/10.1038/ nrc2223
83. Lam EW, Shah K, Brosens JJ. The diversity of sex steroid action: the role of micro-RNAs and FOXO transcription factors in cycling endometrium and cancer. J Endocrinol 2012; 212:13-25; PMID:21382987; http://dx.doi.org/10.1530/JOE-10- 0480
84. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
85. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 1997; 11:1593-607; PMID:9328342; http://dx.doi.org/10.1210/me.11.11.1593
86. Lange CA, Richer JK, Horwitz KB. Hypothesis: Progesterone primes breast cancer cells for crosstalk with proliferative or antiproliferative signals. Mol Endocrinol 1999; 13:829-36; PMID:10379882; http://dx.doi.org/10.1210/me.13.6.829
87. Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991; 11:5032-43; PMID:1922031
88. Modugno F, Laskey R, Smith AL, Andersen CL, Haluska P, Oesterreich S. Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer 2012; 19:R255-79; PMID:23045324; http://dx.doi.org/10.1530/ ERC-12-0175
89. Gabra H, Taylor L, Cohen BB, Lessels A, Eccles DM, Leonard RC, et al. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer 1995; 72:367-75; PMID:7640220; http://dx.doi.org/10.1038/ bjc.1995.340
90. Davis M, Hitchcock A, Foulkes WD, Campbell IG. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996; 56:741-4; PMID:8631007
91. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol 2007; 3:166-73; PMID:17259978; http://dx.doi.org/10.1038/ nchembio860
92. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11:503-11; PMID:21701512; http://dx.doi.org/10.1038/nrc3057
93. Prentice LM, Klausen C, Kalloger S, Köbel M, McKinney S, Santos JL, et al. Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med 2007; 5:33; PMID:18005407; http://dx.doi.org/10.1186/1741-7015-5-33
94. Hagan CR, Regan TM, Dressing GE, Lange CA. ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol 2011; 31:2439-52; PMID:21518957; http://dx.doi.org/10.1128/MCB.01246-10
95. Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA, et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res 2012; 14:R95; PMID:22697792; http://dx.doi.org/10.1186/bcr3211